Haisen Pharm released its 2024 annual performance, with a net profit attributable to the parent company of 123 million yuan, an increase of 17.09%

Haisen Pharm released its 2024 annual report, with operating revenue of 472 million yuan, a year-on-year increase of 18.63%; net profit attributable to the parent company was 123 million yuan, a year-on-year increase of 17.09%. The net profit excluding non-recurring gains and losses was 117 million yuan, a year-on-year increase of 15.02%. Basic earnings per share were 1.22 yuan, with a proposed cash dividend of 1.70 yuan for every 10 shares, and a bonus issue of 4.8 shares. All business segments achieved sales growth, with raw materials, intermediates, and formulations increasing by 16.74%, 35.51%, and 45.82%, respectively